# A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects

> **NCT04135898** · PHASE1 · COMPLETED · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 88 (actual)

## Conditions studied

- Healthy Male

## Interventions

- **DRUG:** SIBP-04
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04135898
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-23
- **Primary completion:** 2020-03-16
- **Final completion:** 2020-03-16
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04135898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04135898, "A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04135898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*